Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises in connection with FinnvedenBulten's application to be listed on NASDAQ OMX Stockholm
Mandate

Vinge advises in connection with FinnvedenBulten's application to be listed on NASDAQ OMX Stockholm

May 09, 2011

Vinge advises in connection with FinnvedenBulten's application to be listed on NASDAQ OMX Stockholm and Nordic Capital's offering of shares in connection therewith. Expected start of trading is on May 20, 2011. Handelsbanken Capital Markets and Carnegie Investment Bank are Joint Lead Managers and Joint Book Runners in the offering.

Vinge's project team is composed primarily of Göran Nyström, Pontus Enquist, Dain Nevonen and Christoffer Benninge as well as Lennart Larsson and Lina Hansson regarding tax matters.

Related

Vinge advised Precise Biometrics

 Vinge has advised Precise Biometrics AB in connection with the merger with Fingerprint Cards.
March 27, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 83 million before transaction costs, with an over-allotment issue of approximately SEK 30 million.
March 26, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

 Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026